CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,491,115
- in 20 filings, $14.5M under 10b5-1 plans
Net −$33,491,115. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 | −6,518 | $16.33 | $106K | 583,911 |
| 2026-03-03 | RUBINSTEIN JULIE President and COO | Option exercise · Stock Option (right to buy) 10b5-1 | −14,722 | 180,603 | ||
| 2026-03-03 | RUBINSTEIN JULIE President and COO | Option exercise · Stock Option (right to buy) 10b5-1 | −11,881 | 451,463 | ||
| 2026-03-03 | GRIFFIN MICHELLE RENEE Director | Option exercise 10b5-1 | +48,044 | $3.99 | $192K | 63,438 |
| 2026-03-03 | GRIFFIN MICHELLE RENEE Director | Sale 10b5-1 | −48,044 | $15.30 | $735K | 15,394 |
| 2026-03-03 | GRIFFIN MICHELLE RENEE Director | Option exercise · Stock Option (right to buy) 10b5-1 | −48,044 | 0 | ||
| 2026-03-03 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −14,233 | $16.52 | $235K | 1,155,291 |
| 2026-03-03 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −50,703 | $15.49 | $785K | 1,936,627 |
| 2026-03-03 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −2,380 | $16.15 | $38K | 1,934,247 |
| 2026-03-02 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −10,000 | $15.72 | $157K | 1,169,524 |
| 2026-03-02 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −289,024 | $15.82 | $4.6M | 1,987,330 |
| 2026-02-27 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −182,891 | $15.99 | $2.9M | 2,276,354 |
| 2026-02-04 | PISKEL KYLE Chief Financial Officer | Option exercise 10b5-1 | +2,145 | $12.14 | $26K | 218,782 |
| 2026-02-04 | PISKEL KYLE Chief Financial Officer | Sale 10b5-1 | −2,145 | $18.46 | $40K | 216,637 |
| 2026-02-04 | PISKEL KYLE Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,145 | 2,146 | ||
| 2026-02-03 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −8,120 | $19.00 | $154K | 1,179,524 |
| 2026-02-02 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −34,668 | $18.60 | $645K | 1,187,644 |
| 2026-02-02 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −124,998 | $18.44 | $2.3M | 2,459,245 |
| 2026-01-12 | PISKEL KYLE Chief Financial Officer | Option exercise 10b5-1 | +4,290 | $12.14 | $52K | 220,927 |
| 2026-01-12 | PISKEL KYLE Chief Financial Officer | Sale 10b5-1 | −4,290 | $18.00 | $77K | 216,637 |
Page 21 of 120 · 2,386 trades